Agilon Health (AGL)
Market Price (12/20/2025): $0.7299 | Market Cap: $302.5 MilSector: Health Care | Industry: Health Care Facilities
Agilon Health (AGL)
Market Price (12/20/2025): $0.7299Market Cap: $302.5 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -90% | Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -167% | Penny stockMkt Price is 0.7 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -374 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.4% | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. | Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.1% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -106% | ||
| High stock price volatilityVol 12M is 103% | ||
| Key risksAGL key risks include [1] an inability to accurately forecast and manage medical costs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -90% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -167% |
| Penny stockMkt Price is 0.7 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -374 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.4% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.1% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1.2%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -106% |
| High stock price volatilityVol 12M is 103% |
| Key risksAGL key risks include [1] an inability to accurately forecast and manage medical costs, Show more. |
Valuation, Metrics & Events
AGL Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Disappointing Second Quarter 2025 Financial Results: Agilon Health reported second-quarter results that fell short of analyst expectations for revenue, medical margin, and EBITDA. The company experienced a gross loss of $52 million, a significant deterioration from the previous year's profit, and medical margin swung to a negative $53 million.
2. Withdrawal of Full-Year 2025 Guidance: The company suspended its previously issued full-year 2025 financial guidance. This action was attributed to ongoing leadership transition, shifts in market dynamics, and the rollout of new performance visibility tools, contributing to investor uncertainty.
3. Leadership Transition and Executive Turnover: CEO Steven Sell stepped down from his role as President, CEO, and Director. Co-founder and Chairman Ronald A. Williams was appointed Executive Chairman to lead an interim Office of the Chairman while the board searched for a permanent CEO replacement.
4. Higher-Than-Expected Medical Costs and Reduced Risk Adjustment Revenue: Agilon Health faced increased medical expenses, particularly from higher-than-expected specialist visits, Part B drugs, outpatient surgeries, and supplemental benefits. Additionally, the company projected significant shortfalls in risk adjustment revenue for both 2024 and 2025.
5. Analyst Downgrades and Revised Outlooks: Following the challenging financial results and outlook, several analysts significantly lowered their price targets and financial projections for Agilon Health, reflecting diminished confidence in the company's near-term performance. For instance, Barclays lowered its price target by 50% to $1.50 from $3.00.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AGL Return | � | � | -40% | -22% | -85% | -63% | � |
| Peers Return | � | � | -24% | -7% | -24% | 14% | � |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| AGL Win Rate | � | 38% | 50% | 58% | 33% | 33% | |
| Peers Win Rate | � | 39% | 53% | 48% | 35% | 53% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| AGL Max Drawdown | � | � | -44% | -34% | -87% | -73% | |
| Peers Max Drawdown | � | � | -50% | -32% | -45% | -34% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: PRVA, ASTH, PIII, ALHC, INNV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/19/2025 (YTD)
How Low Can It Go
| Event | AGL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -75.4% | -25.4% |
| % Gain to Breakeven | 307.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to
In The Past
Agilon Health's stock fell -75.4% during the 2022 Inflation Shock from a high on 6/18/2021. A -75.4% loss requires a 307.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Agilon Health Earnings Notes | |||
| With Agilon Health Stock Surging, Have You Considered The Downside? | Return | ||
| Day 6 of Gains Streak for Agilon Health Stock with 45% Return (vs. -34% YTD) [8/19/2025] | Notification | ||
| Day 5 of Gains Streak for Agilon Health Stock with 42% Return (vs. -35% YTD) [8/18/2025] | Notification | ||
| Agilon Health (AGL) Operating Income Comparison | Financials | ||
| Agilon Health (AGL) Debt Comparison | Financials | ||
| Agilon Health (AGL) Net Income Comparison | Financials | ||
| Agilon Health (AGL) Tax Expense Comparison | Financials | ||
| Agilon Health (AGL) EBITDA Comparison | Financials | ||
| Agilon Health (AGL) Operating Cash Flow Comparison | Financials | ||
| ARTICLES | |||
| Market Movers | Winners: SATS, UP, DOMO | Losers: AGL, TRNS, VTLE | August 26th, 2025 | ||
| AGL Stock Up 45% after 6-Day Win Streak | August 20th, 2025 | ||
| AGL Stock Up 42% after 5-Day Win Streak | August 19th, 2025 | ||
| Market Movers | Winners: AMRC, STAA, XMTR | Losers: AGL, BRBR, INSP | August 6th, 2025 | ||
| AGL Stock Down -26% after 7-Day Loss Streak | August 2nd, 2025 |
Trade Ideas
Select past ideas related to AGL. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Agilon Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 13.21 |
| Mkt Cap | 1.0 |
| Rev LTM | 2,470 |
| Op Inc LTM | -0 |
| FCF LTM | 66 |
| FCF 3Y Avg | -19 |
| CFO LTM | 75 |
| CFO 3Y Avg | 4 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.7% |
| Rev Chg 3Y Avg | 28.1% |
| Rev Chg Q | 23.8% |
| QoQ Delta Rev Chg LTM | 5.6% |
| Op Mgn LTM | -0.1% |
| Op Mgn 3Y Avg | -3.6% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 4.3% |
| CFO/Rev 3Y Avg | -0.4% |
| FCF/Rev LTM | 3.7% |
| FCF/Rev 3Y Avg | -1.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 0.7 |
| P/EBIT | -0.5 |
| P/E | -0.5 |
| P/CFO | 14.7 |
| Total Yield | -1.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -1.8% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 13.8% |
| 3M Rtn | -4.2% |
| 6M Rtn | 3.8% |
| 12M Rtn | -7.3% |
| 3Y Rtn | -13.5% |
| 1M Excs Rtn | 10.9% |
| 3M Excs Rtn | -6.4% |
| 6M Excs Rtn | -11.1% |
| 12M Excs Rtn | -22.5% |
| 3Y Excs Rtn | -89.5% |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | 4.0% | -14.6% | -9.9% |
| 5/6/2025 | -24.0% | -39.5% | -52.9% |
| 2/25/2025 | -7.4% | -12.7% | 24.5% |
| 11/7/2024 | -34.1% | -38.7% | -19.7% |
| 8/6/2024 | -9.3% | -10.3% | -34.4% |
| 5/7/2024 | 4.2% | 10.4% | 36.5% |
| 2/27/2024 | -1.9% | -7.7% | -11.6% |
| 11/2/2023 | -13.2% | -30.9% | -32.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 7 | 5 |
| # Negative | 8 | 9 | 11 |
| Median Positive | 4.1% | 8.3% | 24.5% |
| Median Negative | -9.8% | -12.7% | -11.6% |
| Max Positive | 16.0% | 15.9% | 36.5% |
| Max Negative | -34.1% | -39.5% | -52.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/30/2025 |
| 6302025 | 8042025 | 10-Q 6/30/2025 |
| 3312025 | 5062025 | 10-Q 3/31/2025 |
| 12312024 | 2252025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5072024 | 10-Q 3/31/2024 |
| 12312023 | 2272024 | 10-K 12/31/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5092023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11032022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 3032022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |